Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032931 | 0.87 | CA2 (0.47) | CA2CA1CA9 | |
| SCHEMBL4953881 | 0.80 | CA2 (0.43) | CA2CA1CA9 | |
| SCHEMBL4949086 | 0.80 | CA2 (0.43) | CA2CA1CA9 | |
| SCHEMBL4949681 | 0.80 | CA2 (0.43) | CA2CA1CA9 | |
| SCHEMBL1759254 | 0.78 | CA2 (0.42) | CA2CA1CA9 | |
| SCHEMBL575713 | 0.77 | CA2 (0.44) | CA2CA1CA9 | |
| SCHEMBL576009 | 0.77 | CA2 (0.44) | CA2CA1CA9 | |
| SCHEMBL1191830 | 0.76 | CA2 (0.41) | CA2CA1CA9 | |
| SCHEMBL1759184 | 0.76 | CA2 (0.41) | CA2CA1CA9 | |
| SCHEMBL1759185 | 0.76 | CA2 (0.41) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670758-B1 | PROCESS FOR MAKING TRISUBSTITUTED SILYLOXYETHYL TRIFLATES | SYNTHON BV (NL) | 2022-09-28 | — | — | EP | claimed |
| US-9938297-B2 | Process for the synthesis of everolimus and intermediates thereof | Cipia Limited (IN) | 2018-04-10 | — | — | US | claimed |
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | CIPLA LIMITED (IN) | 2017-08-03 | — | — | US | claimed |
| EP-3166950-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | Cipla Limited (IN) | 2017-05-17 | — | — | EP | claimed |
| WO-2016020664-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2016-02-11 | — | — | WO | claimed |
| US-9938297-B2 | Process for the synthesis of everolimus and intermediates thereof | Cipia Limited (IN) | 2018-04-10 | — | — | US | disclosed |
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | CIPLA LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
| EP-3166950-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | Cipla Limited (IN) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016020664-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | MTOR, RICTOR, RPTOR | CA2 3423/4885CA1 4266/4885CA9 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.